Director dealing

EDX Medical Group PLC

23 December 2025

 

23 December 2025

EDX Medical Group plc · EDX

AQSE: EDX

("EDX Medical" or the "Company")

Director dealing

CAMBRIDGE, UK: EDX Medical Group plc ("EDX Medical", the "Company" or the "Group"), which develops innovative digital diagnostic products and services for the personalised treatment for cancer, heart disease and infectious diseases, announces that it was informed yesterday that Dr Michael Hudson, Chief Executive Officer of the Company, purchased a total of 28,526 ordinary shares in the Company on 22 December 2025, at an average price per share of 10.57 pence. Dr Hudson now holds 20,600,000 ordinary shares in the Company.

The Company was also informed yesterday that Sebastian Hudson, a person closely associated with Dr Michael Hudson, purchased 22,500 shares on 22 December 2025, at an average price per share of 10.03 pence. Mr Hudson now holds 50,000 ordinary shares in the Company.

Taken together, Dr Hudson controls 20,650,000 ordinary shares, representing 5.34% of the Company's issued share capital.

This announcement is made in accordance with Article 19(1) of the EU Market Abuse Regulation as incorporated into UK law through the European Union (Withdrawal) Act 2018. The directors of the Company accept responsibility for the contents of this announcement.

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Dr Michael Hudson
2	Reason for the notification
a)	Position/status	PDMR / Chief Executive Officer
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group PLC
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)
			Price	Volume
			£0.1075	13,624
			£0.1040	14,902
d)	Aggregated information
	- Aggregated volume	28,526
	- Price	£0.1057
e)	Date of the transaction	2025-12-22
f)	Place of the transaction	AQSG - Aquis Growth Market (Equity)

1	Details of the person discharging managerial responsibilities / person closely associated
a)	Name	Sebastian Hudson
2	Reason for the notification
a)	Position/status	Person Closely Associated with Dr Michael Hudson
b)	Initial notification /Amendment	Initial notification
3	Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor
a)	Name	EDX Medical Group PLC
b)	LEI	213800BZVJZTMCZ6DJ63
4	Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)	Description of the financial instrument, type of instrument	Ordinary Shares of £0.01 each
	Identification code	ISIN: GB00BNDMJS47
b)	Nature of the transaction	Purchase of shares
c)	Price(s) and volume(s)
			Price	Volume
			£0.1020	7,425
			£0.0995	15,075
d)	Aggregated information
	- Aggregated volume	22,500
	- Price	£0.1003
e)	Date of the transaction	2025-12-22
f)	Place of the transaction	AQSG - Aquis Growth Market (Equity)

ENDS

Contacts: 

EDX Medical Group plc
Dr Mike Hudson  (Chief Executive Officer)	[phone]
Oberon Capital
Nick Lovering (Corporate Adviser) Adam Pollock (Corporate Broking) Mike Seabrook (Corporate Broking)	[phone]
Media House International
Ramsay Smith Gary McQueen	[phone] [e-mail] [phone] [e-mail]
IFC Advisory (Investor Relations)
Tim Metcalfe Graham Herring	[phone]

Notes to Editors:

About EDX Medical Group plc

The EDX Medical Group plc is listed on the Apex Segment of the AQSE Growth Market (TIDM: EDX).

EDX Medical was founded by Professor Sir Christopher Evans, OBE, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO, Dr Mike Hudson.

By translating clinical insights into pragmatic solutions combining advanced biological and digital technologies, EDX Medical seeks to cost effectively improve the detection and characterisation of disease to personalise treatment in a timely fashion. Early disease detection and biologically based personal treatment optimisation is considered to be the most impactful way of improving patient outcomes, reducing deaths and lowering the cost of healthcare globally.

EDX Medical Group provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services. The Company operates its own facilities in Cambridge and Oxford, UK, and has strategic product and technology partnerships with organisations such as Thermo Fisher EMEA Ltd, a world leader in supplying life sciences solutions and services.

www.edxmedical.com

 

END